CNSL.L

Cambridge Nutritional Sciences
Cambridge Nutrition. - Issue of Equity and Total Voting Rights
30th January 2024, 12:50
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 4011B
Cambridge Nutritional Sciences PLC
30 January 2024
 

Cambridge Nutritional Sciences plc

(the "Company" or "CNS")

 

Issue of Equity and Total Voting Rights

 

Cambridge Nutritional Sciences plc (AIM: CNSL), the specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition, announces that it has allotted 265,480 new ordinary shares of 4 pence each in the capital of the Company ("Ordinary Shares") to the trustee of its existing employee benefit trust (the "EBT") at a price of 4 pence each, being their nominal value.

 

The above issue and allotment of the new Ordinary Shares will enable the EBT to satisfy employee incentive awards granted to employees of the Company and its wider group.

 

Application has been made to the London Stock Exchange for the new Ordinary Shares to be admitted to trading on AIM. It is anticipated that the new Ordinary Shares, which will rank pari passu in all respects with the Company's existing Ordinary Shares, will be admitted to trading on AIM on 2 February 2024 ("Admission"). Following Admission, the Company's issued share capital will comprise 237,950,660 Ordinary Shares with voting rights and that figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules. The Company does not hold any shares in treasury.

 

Contacts: 

 

Cambridge Nutritional Sciences plc 

www.cnsplc.com

Jag Grewal, Chief Executive Officer 

via Walbrook PR





Cavendish Capital Markets Limited  

Tel: 020 7220 0500

Geoff Nash / Edward Whiley / George Dollemore (Corporate Finance)


Nigel Birks / Harriet Ward (ECM)

 






Walbrook PR Limited

Tel: 020 7933 8780 or CNS@walbrookpr.com

Paul McManus / Charlotte Edgar

Mob: 07980 541 893 / Mob: 07884 664 686

Sam Allen

Mob: 07502 558 258

 

About Cambridge Nutritional Sciences plc

Cambridge Nutritional Sciences plc (AIM: CNSL) is a specialist medical diagnostics company focused on industry-leading Health and Nutrition products.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOEEAAFEDLNLEFA]]>
TwitterFacebookLinkedIn